New weight-loss shot appears to outperform other obesity drugs on market

Eli Lilly announced that its new weight-loss drug, retatrutide, has demonstrated significant efficacy in a large clinical trial, with participants losing an average of 28% of their body weight over 80 weeks. This performance surpasses that of existing obesity medications on the market.

The successful results of retatrutide could position Eli Lilly as a leader in the weight-loss drug market, especially as it follows the recent FDA approval of another weight-loss medication, Foundayo, further expanding its portfolio in this competitive sector.

While the promising weight-loss results are noteworthy, concerns have emerged regarding potential emotional side effects associated with retatrutide, as some users report experiences of emotional flattening, raising questions about the overall impact of such drugs on mental health and personal relationships.